10 GHP Healthcare and Pharmaceutical Awards 2026 Located in the Midlands, UK, Dalgety UK Ltd (Dalgety) is a cultivator of cannabisbased products for medicinal use (CBPMs), operating within a regulated clinical framework. It is the only cultivator in the UK to have achieved EU-GMP certification for the cultivation, manufacture, and supply of the cannabis flower as an active pharmaceutical ingredient (API). It does so while contributing toward the development of a reliable domestic supply chain within a rapidly evolving sector. At the same time, the company prioritises education, data, and the provision of clear, accurate information to support clinicians in navigating medical cannabis and making knowledgeable prescribing decisions. We speak to Chief Commercial Officer, Matt Clifton to learn more. Matt begins by telling us how one of the biggest challenges in the medical cannabis industry is perception versus reality. Medical cannabis is talked about in two extremes – either oversimplified or exaggerated – which makes it hard for patients and clinicians to gain a clear understanding. This is while the evidence continues to evolve, which makes handling it carefully and responsibly important. Meanwhile, there are also the practical challenges – Heavy reliance on imports and fragmented supply chains add complexity. As a UK-based cultivator, Dalgety aims to help build a more stable and transparent supply framework. “Dalgety was built with a clear intention,” Matt tells us. “To align cannabis cultivation with pharmaceutical standards from day one.” He continues, “Our values are centred on patient safety, scientific rigour, and long-term credibility. We believe that the future of medical cannabis depends on the industry holding itself to the same standards as other areas of medicine. That means prioritising consistency over novelty, evidence over assumption, and responsibility over shortterm commercial gain. These values shape how we operate day-today, from cultivation practices through to how we communicate as a business. In an industry that can at times be polarised, maintaining a measured and balanced approach has been critical to building trust with clinicians, regulators, and partners.” Dalgety’s facility has seen significant investment, with it being designed to allow for a high level of environmental control, consistency, and quality assurance. As a result of this commitment, the company has achieved EU-GMP certification for the cultivation of the cannabis flower as an API. Matt tells us that it is the company’s prioritisation of clinical credibility and operational excellence that has given it that leading edge – while others within the industry have leaned more toward branding or lifestyle promotion. As such, Dalgety’s focus extends beyond cultivation into data, consistency, and playing a responsible role in supporting prescribing decisions. “Medical cannabis should be viewed through the same lens as any other area of medicine. Progress in this space will come from data, consistency, and responsible practice, rather than broad claims or short-term trends. At Dalgety, we see our role as contributing to that progression, both through the products we produce and the standards we uphold.” Over the past year, the company has been scaling both its operational capability and its role within the UK market. It is actively progressing additional licencing so it can go beyond cultivation into a broader range of medical formats, including exploring opportunities across the supply chain, from processing through to the partnerships that support patient access. Additionally, it has invested in industry-wide education initiatives, including Medical Cannabis Awareness Month, to support greater understanding of CBPMs within a clinical context, as well as liaised the police, to keep them informed. This comes alongside an internal focus on refining its cultivation processes to ensure consistent, repeatable outputs, recognising that in a medical setting, reliability is just as important as innovation. Looking ahead, Dalgety will continue to focus on measured expansion, as Matt tells us, “2026 is a year of building on strong foundations, ensuring that as the market grows, we are positioned to scale in a way that remains consistent with our values and standards.” With all of that in mind, he concludes, “Medical cannabis should be viewed through the same lens as any other area of medicine. Progress in this space will come from data, consistency, and responsible practice, rather than broad claims or short-term trends. At Dalgety, we see our role as contributing to that progression, both through the products we produce and the standards we uphold.” Company name: Dalgety UK Ltd Contact name: Matt Clifton Email: matt.clifton@dalgetyuk.co.uk Website: www.dalgetyuk.co.uk Botanical Medicine Excellence Award 2026
RkJQdWJsaXNoZXIy MTUyMDQwMA==